Roxithromycin

Roxithromycin is semisynthetic derivative of erythromycin A. Among its listed roles, it functions as a antibacterial drug. It is an erythromycin derivative, a macrolide and a semisynthetic derivative. Functionally, it is related to erythromycin A. Roxithromycin is a semi-synthethic macrolide antibiotic that is structurally and pharmacologically similar to [erythromycin], [azithromycin], or [clarithromycin]. It was shown to be more effective against certain Gram-negative bacteria, particularly Legionella pneumophila. Roxithromycin exerts its antibacterial action by binding to the bacterial ribosome and interfering with bacterial protein synthesis. It is marketed in Australia as a treatment for respiratory tract, urinary and soft tissue infections. It is grouped under the following drug class(es): Macrolides. Its therapeutic use is listed as anti-infectives, antibacterials and antibiotics. The directory classifies it as a commercial API with a semi-synthetic source/manufacturing origin. Other names for this substance include Rulide (TN), NSC-758443 and Infectoroxit. Its PubChem CID is 6915744.

CAS No 80214-83-1
Molecular Formula C41H76N2O15
Molecular Weight 837.0 g/mol
Synonyms (3R,4S,5S,6R,7R,9R,10E,11S,12R,13S,14R)-6-[(2S,3R,4S,6R)-4-(dimethylamino)-3-hydroxy-6-methyloxan-2-yl]oxy-14-ethyl-7,12,13-trihydroxy-4-[(2R,4R,5S,6S)-5-hydroxy-4-methoxy-4,6-dimethyloxan-2-yl]oxy-10-(2-methoxyethoxymethoxyimino)-3,5,7,9,11,13-hexamethyl-oxacyclotetradecan-2-one

Zoho Contact Form

"*" indicates required fields

I am a*
This field is for validation purposes and should be left unchanged.

Frequently Asked Questions